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Summary
 
In normal hemopoietic cells that are dependent on specific growth factors for cell survival, the
expression of the basic helix-loop-helix transcription factor SCL/Tal1 correlates with that of
c-Kit, the receptor for Steel factor (SF) or stem cell factor. To address the possibility that SCL
may function upstream of c-kit, we sought to modulate endogenous SCL function in the
CD34
 
1
 
 hemopoietic cell line TF-1, which requires SF, granulocyte/macrophage colony–stim-
ulating factor, or interleukin 3 for survival. Ectopic expression of an antisense SCL cDNA (as-
SCL) or a dominant negative SCL (dn-SCL) in these cells impaired SCL DNA binding activ-
ity, and prevented the suppression of apoptosis by SF only, indicating that SCL is required for
c-Kit–dependent cell survival. Consistent with the lack of response to SF, the level of c-kit
mRNA and c-Kit protein was significantly and specifically reduced in as-SCL– or dn-SCL–
expressing cells. c-kit mRNA, c-kit promoter activity, and the response to SF were rescued by
SCL overexpression in the antisense or dn-SCL transfectants. Furthermore, ectopic c-kit ex-
pression in as-SCL transfectants is sufficient to restore cell survival in response to SF. Finally,
enforced SCL in the pro–B cell line Ba/F3, which is both SCL and c-kit negative is sufficient
to induce c-Kit and SF responsiveness. Together, these results indicate that c-kit, a gene that is
essential for the survival of primitive hemopoietic cells, is a downstream target of the transcrip-
tion factor SCL.
Key words: SCL • TAL1 • c-kit • apoptosis • Steel factor 
CL, also known as TAL1 or Tcl-5, is associated with
25% of chromosomal rearrangements in childhood T
cell acute lymphoid leukemia (1–6). SCL codes for a he-
mopoietic-specific transcription factor of the basic helix-loop-
helix family, and can enhance or suppress transcription (7).
SCL expression is detected in primitive pluripotent he-
mopoietic precursors (8, 9), in a subset of CD34
 
1
 
 cells, in
mast cells and megakaryocytes (8, 10, 11) and in maturing
erythroid cells (9, 12–16). Consistent with a role for SCL
in establishing the hemopoietic lineage, a targeted disrup-
tion of the SCL gene specifically abrogates blood cell for-
mation, resulting in embryonic lethality at day E8.5 (17,
18). Moreover, scl
 
2
 
/
 
2
 
 embryonic stem cells fail to contrib-
ute to hemopoietic stem cells and blood cells in chimeric
mice, further suggesting a critical role of SCL for the devel-
opment of all hemopoietic lineages (19, 20). Together,
these results suggest that SCL is required for mesodermal
cell commitment into hemopoietic stem cells and/or is es-
sential for the survival of hemopoietic stem cells.
SCL binds DNA only upon interaction with the ubiqui-
tous basic helix-loop-helix transcription factors E2A or
HEB (7, 21). The SCL-E2A heterodimer preferentially
binds the TAL1 consensus AA
 
CAGATG
 
GT defined by in
vitro binding site selection (CASTing). SCL represses the
E2A-dependent activity directed from the TAL1 consensus
in front of a minimal promoter, but relieves the inhibition
conferred by Id1 on E2A (7). However, the TAL1 consen-
sus has not been found in any known hemopoietic pro-
 
S
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moter. SCL also associates with Lmo-2 or RBTN-2, a
RING finger protein (22–25) in a multiprotein complex
that includes E2A, GATA-1, an erythroid zinc finger tran-
scription factor (26), and a novel LIM-binding protein,
Ldb1 (24), and selectively binds an Ebox-GATA motif also
defined by cycle amplification and selection of targets
(CASTing). Although similar motives are found on two
erythroid promoters, those of the glycophorin A and B
genes and the porphobilinogen deaminase gene, their con-
tribution to promoter activity in response to SCL has not
been established (24). Finally, in T-ALL, SCL upregulates
the expression of a cell surface marker, TALLA-1 (27).
However, it is not clear whether TALLA-1 is a direct tar-
get of SCL. Thus, despite observations that indicate a cru-
cial role for SCL in normal hemopoiesis and T cell leuke-
mogenesis, no natural binding site or SCL target gene has
been as yet reported.
The survival of hemopoietic cells both in culture and in
vivo is critically dependent on the presence of hemopoietic
growth factors that act to suppress apoptosis (28–30). The
importance of such growth factors for blood cell develop-
ment was first revealed by the genetics of hereditary ane-
mias in mice. Perhaps the best studied examples are white
spotting and Steel mice that are severely anemic due to
mutations in the genes encoding the tyrosine kinase recep-
tor c-kit (31) or its ligand Steel factor (SF),
 
1
 
 respectively
(32, 33). Severe mutations result in lethality in homozy-
gotes (for review see references 34, 35), indicating a crucial
role for these two genes in hemopoiesis. We and others
have previously shown that SF suppresses apoptosis in early
hemopoietic cells that express the surface antigen CD34
(32, 36), and in the CD34
 
1
 
 cell line TF-1 (28). SF has also
been shown to synergize with IL-7 in delaying apoptosis in
primitive thymocytes (37–39).
The expression pattern of SCL in primary hemopoietic
cells parallels that of c-kit (8), suggesting that SCL functions
in concert with c-Kit. Furthermore, a two- to fourfold
augmentation of SCL protein was observed in maturing
erythroid progenitors stimulated with SF (16). However, it
is not known whether upregulation of SCL is a cause or
consequence of c-Kit activation, cell survival, or cell prolif-
eration. Because of the correlation between c-Kit and SCL
expression, we directly investigated the relationship of SCL
function relative to c-Kit through the attenuation of SCL pro-
tein levels in TF-1 cells using an antisense SCL (as-SCL)
expression vector, or through expression of a dominant
negative SCL (dn-SCL). We reasoned that SCL function is
likely to be determined by the nature of its binding part-
ners, which have yet to be defined in CD34
 
1
 
 cells. We
therefore chose to investigate this through the disruption of
endogenous SCL function in the CD34
 
1
 
 hemopoietic cell
line TF-1, which should express appropriate SCL binding
partners. Moreover, TF-1 has retained one of the most im-
portant characteristics of primary hemopoietic cells (9, 40),
i.e., their requirement in hemopoietic growth factors for
cell survival (28, 41). Our approach to defining SCL func-
tion and SCL target(s) was to disrupt SCL in TF-1 cells and
to screen stable transfectants with a functional assay, i.e.,
cell survival in response to different growth factors.
 
Materials and Methods
 
Cell Lines, Growth Factors, and Antibodies
 
.
 
The TF-1 cell line
(40) was a gift from Dr. T. Kitamura (DNAX, Palo Alto, CA). The
cells were maintained in IMDM (GIBCO BRL, Gaithersburg,
MD) supplemented with 10% FCS (GIBCO BRL) and 5 ng/ml
human GM-CSF. The cells were passaged every second day at
1.5 
 
3 
 
10
 
5
 
/ml. Jurkat T cells were also maintained in IMDM sup-
plemented with FCS (10%), and were passaged three times
weekly at a concentration of 1.5 
 
3 
 
10
 
5
 
/ml.
Purified recombinant human GM-CSF was a gift from Dr.
Steve Clark (Genetics Institute, Cambridge, MA) and purified re-
combinant SF was from Dr. K. Langley (Amgen, Thousand
Oaks, CA). The monoclonal antibody 2TL136 specific for hu-
man SCL was provided by Dr. Danièle Mathieu-Mahul (IN-
SERM, Marseille, France; references 10, 42). The monoclonal
antibody ACK2 is specific for murine c-Kit (GIBCO BRL). The
monoclonal mouse anti–human c-Kit was from Cedarlane Labs.
(Hornby, Ontario, Canada). The monoclonal mouse anti–rabbit
eIF-4E cross-reacts with the human protein (Transduction Labs.,
Lexington, KY). The monoclonal anti-CD45 (clone 4B2; ATCC
number HB 196, American Type Culture Collection, Rockville,
Maryland) was used at 1:10 dilution of hybridoma supernatant.
Monoclonal anti–hGM-CSF receptor 
 
b
 
 chain was purchased
from Upstate Biotechnology, Inc. (Lake Placid, NY) and used at
a 1:100 dilution. Annexin V was purchased from Biodesign (Ken-
nebunk, ME), and used at a concentration of 400 mg/ml.
 
Retrovirus Production and Infection.
 
The human SCL cDNA,
the dn-SCL devoid of DNA binding domain (12) and the as-SCL
were all cloned in the EcoRI site of the murine stem cell virus
(MSCV)-neo vector (43). High titer amphotropic viruses (10
 
6
 
PFU/ml) were produced by transient transfection into BING
cells (44). The cells were irradiated and used for coculture with
TF-1 cells for 48 h. Murine c-kit cloned in the LXSN retroviral
vector was a gift from Dr. A. Bernstein (Samuel Lunenfeld Re-
search Institute, Toronto, Ontario, Canada). Ecotropic viruses
were produced by transfection into the BOSC23 packaging cell
line (44).
For retroviral infection, 10
 
6
 
 exponentially growing cells (TF-1
or A31) were presensitized with polybrene at 2 
 
m
 
g/ml for 24 h
and cocultured with virus-producing clones for another 24 h.
Nonadherent TF-1 cells were separated from the infected fibro-
blasts. A polyclonal population was analyzed 7 d after selection in
G418 at 1 mg/ml. For long-term experiments, cloning was per-
formed through limiting dilution (12).
 
Plasmids and Transfection
 
.
 
The human SCL cDNA was cloned
in the antisense orientation under the control of the metallothio-
nein promoter by digesting the plasmid pMSCL (12) with EcoRI
and religation. The EcoRI sites come from the plasmid polylinker.
Stable TF-1 transfectants harboring the as-SCL were obtained
through Lipofectin-mediated DNA transfer (GIBCL BRL) as
previously described (9, 12). Cells were cloned immediately after
gene transfer by limiting dilution, and the selective pressure was
applied the following day, at a concentration of 1 mg/ml G418
(GIBCO BRL). GM-CSF was present throughout the gene
 
1
 
Abbreviations used in this paper:
 
 as-SCL, antisense SCL; dn-SCL, dominant
negative SCL; GAPDH, rat glyceraldehyde-3-phosphate dehydrogenase;
MSCV, murine stem cell virus; SF, Steel factor. 
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transfer procedure. After selection, G418 concentrations were
lowered to 400 
 
m
 
g/ml in order to expand the cells and prepare a
large stock of frozen cells immediately after characterization. Each
cell line was kept for not more than 2 mo in culture.
 
Nuclear Staining for SCL.
 
3 
 
3 
 
10
 
5
 
 TF-1 and as-SCL transfec-
tants were fixed in 500 
 
m
 
l of Bouin’s fixative for 15 min at room
temperature. The cells were then pelleted at 200 
 
g
 
 for 5 min and
resuspended in 200 
 
m
 
l of 0.2% Triton X-100, followed immedi-
ately with 800 
 
m
 
l of PBS. The cells were pelleted again, washed
with 1 ml of PBS, and resuspended in 100 
 
m
 
l of 1:10 dilution of
anti-SCL monoclonal antibody (clone BTL73, provided by Dr.
Danièle Mathieu-Mahul). After 30 min of incubation on ice, cells
were washed twice with 1 ml of PBS followed by a 10-min wash
in 1 ml of PBS, resuspended in 100 
 
m
 
l of FITC-coupled goat
anti–mouse antibody at the recommended dilution (Caltech, San
Francisco, CA), and incubated for 30 min at 4
 
8
 
C. The cells were
washed as above before flow cytometry analysis.
 
Surface Marker Staining.
 
For surface marker staining, 3–5 
 
3
 
10
 
5
 
 cells were washed once with PBS supplemented with 2% FBS
and 0.05% sodium azide (staining buffer), labeled with the primary
antibody for 30 min on ice in a total volume of 100 ml, washed
three times with 1 ml of staining buffer, and labeled with a bioti-
nylated goat anti–mouse antibody (Cedarlane, Labs.) in staining
buffer supplemented with 1% normal goat serum (Sigma-Aldrich,
Oakville, Ontario, Canada) for 30 min on ice. After washing, the
cells were incubated with PE-conjugated streptavidin (Sigma) for
an additional 30 min on ice, washed, and analyzed on the FACS-
can
 
Ò
 
 flow cytometer (Becton Dickinson, San Jose, CA).
 
Northern Blotting Analysis.
 
Cells were homogenized in the
presence of guanidium and RNA isolated by acid-phenol extrac-
tion as previously described (9, 45). Northern blotting and hy-
bridization were performed as previously described (9). Probes
used were the 1.2-kb Hind–XbaI human SCL cDNA fragment
(nucleotides 109–1293; reference 12), the 1.4-kb SalI–XbaI frag-
ment of human GATA-1 cDNA (26), a 1.5- kb DraI–KpnI hu-
man c-kit cDNA fragment from human c-kit–BS plasmid (gift
from Dr. J. Simms, Immunex, Seattle, WA), and the 1.2-kb PstI–
XbaI fragment of the rat glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) cDNA (46). Blots were exposed to a Phosphor-
Imager screen for quantitation.
 
Western Blotting Analysis.
 
Cell lysates were prepared as de-
scribed previously (42). Protein concentrations were determined
with the Bio-Rad Protein Assay reagent (Bio-Rad, Hercules,
CA). Equal amounts of proteins (20 
 
m
 
g) were loaded on a 12%
SDS-polyacrylamide gel and transferred to nitrocellulose using
the mini “Transblot” (Bio-Rad) for 1 h at 100 V.
Membranes were blocked in 5% nonfat dry milk and 1% BSA,
incubated with 2TL13G hybridoma tissue culture medium (mono-
clonal anti-SCL) diluted 1:300 for 2.5 h at room temperature,
washed, incubated with a goat anti–mouse alkaline phosphatase–
linked antibody (Bio-Rad), diluted 1:1,000 for 1.5 h, and washed
extensively. Western blots were then developed by incubating
membranes in the dark with 10 ml of BCIP (165 
 
m
 
g/ml) and
NBT (330 
 
m
 
g/ml) (GIBCO BRL) for 2 min, and the reaction was
terminated by several washes with water as described previously
(42). In parallel, Western blotting was performed with a mono-
clonal antibody against the eukaryotic translation initiation factor
(eIF-4E) (Transduction Labs.) as a control for protein loading.
 
Electrophoretic Mobility Shift Assays
 
Nuclear extracts were prepared as previously described (47).
Protein concentrations were assayed with the Bio-Rad Protein
Assay reagent. Binding reactions for electrophoretic mobility shift
assays were performed as previously described (42). In brief, the
binding reactions were allowed to proceed at room temperature
for 15 min in the presence of 0.5 
 
m
 
g of poly(dI-dC) as nonspecific
competitor DNA in 20 mM Hepes (pH 7.5), 50 mM KCl, 1 mM
dithiothreitol, 1 mM EDTA, 5% glycerol, 10 
 
m
 
g BSA, 100,000
cpm double-stranded synthetic oligonucleotide, and 25 
 
m
 
g nu-
clear extract in a total volume of 10 
 
m
 
l. 50-fold molar excess of
unlabeled oligonucleotides were used for self-competition and
added before nuclear extracts. For antibody supershift assays, 200 ng
of affinity-purified anti-E2A (Santa Cruz Biotechnology, Santa
Cruz, CA), 1 
 
m
 
l of the monoclonal anti-SCL antibody (BTL73;
reference 48), or 1 
 
m
 
l of an unrelated antibody were added to the
binding reaction. Protein complexes were resolved by electro-
phoresis on 4% polyacrylamide gel buffered in 0.25
 
3 
 
Tris-borate–
EDTA, 195 mM glycine (pH 8.5) at 4
 
8
 
C. The sequences of the
probes (coding strand) are: ACCTGAA CAGATG GTCGGCT
TAL1 consensus (21); CTAGGGAG CACCTG CCAGGTG
GCTGGCCC murine c-kit probe (49); and an E box probe de-
rived from the rat POMC E box also referred to as DE2c (50).
 
c-kit Promoter Constructs, Transfection Protocols, and Luciferase As-
say.
 
The human c-kit promoter was cloned by PCR from ge-
nomic DNA to generate a fragment that extends from 1146 bp
upstream of the transcription initiation site to 43 bp downstream.
In brief, genomic DNA was amplified in two steps, the first PCR
providing a fragment that extends from position 
 
2
 
634 to 
 
1
 
60
(PCR1), and the second PCR a fragment that covers 
 
2
 
1146 to
 
2
 
379 (PCR2). PCR1 was cut with SalI and BamHI and PCR2
with HindIII (site added) and SalI, and the fragments were cloned
into the HindIII and BglII sites of the promoterless luciferase ex-
pression vector pXPII to generate kit 1146. The chimeric construct
was verified through sequencing. TF-1 and A31 cell lines were
transfected by electroporation. Cells were passaged 24 h before
gene transfer at a concentration of 3 
 
3 
 
10
 
5
 
 cells/ml. Exponentially
growing cells were then concentrated at 2.5 
 
3 
 
10
 
7
 
 cells/ml and
electroporated at 900 
 
m
 
F and 350 mV using a Bio-Rad electropo-
rator with 12 
 
m
 
g of reporter DNA and 1.5 
 
m
 
g of CMV 
 
b
 
-galac-
tosidase used as an internal control for the experiment, with or
without different molar ratios of MSCV-SCL as shown; the total
amount of transfected DNA was then filled to 25 
 
m
 
g with pGEM4
as a carrier. Cell lysates were prepared 15 h after transfection, nor-
malized for 
 
b
 
-galactosidase content, and assayed for luciferase activ-
ity. Rous Sarcoma virus–driven luciferase (RSV-luc) was used as an
external control for all the transfections and pXP2 as a negative
control as described previously (47).
 
Apoptosis Assays.
 
Analysis of DNA fragmentation by agarose
gel electrophoresis was performed as previously described (28). In
brief, equal cell numbers were lysed in Sarkosyl buffer and treated
with Proteinase K and RNase A before loading on a 1.2% agarose
gel (20 cm), followed by a 16-h electrophoresis at 40 V. Cell via-
bility was independently confirmed through trypan blue exclu-
sion and counting (28, 29), or the double fluorochrome staining
assay, as described below. Apoptosis was also assessed by flow cy-
tometry analysis of cells labeled with Annexin V-FITC (1 
 
m
 
g/ml),
shown previously to be an early marker of apoptosis (51, 52). Im-
mediately before acquisition, 1 ml of propidium iodide solution
(1 mg/ml) was added in order to detect dead cells.
 
Double Fluorochrome Staining Assay.
 
A stock solution of dye
mix containing 100 
 
m
 
g/ml acridine orange and 100 
 
m
 
g/ml ethid-
ium bromide was prepared in PBS. Cell were resuspended at 5 
 
3
 
10
 
5
 
 to 5 
 
3 
 
10
 
6
 
 in IMDM. 1 
 
m
 
l of dye mix was added to 25 
 
m
 
l of
cell suspension, and 10 
 
m
 
l of the mixture was placed on a micro-
scope slide for examination by fluorescent microscopy (Leica, 
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Wetzlar, Germany). Cells with bright green chromatin were con-
sidered viable cells while those with bright orange chromatin or
collapsed chromatin were considered dead cells. A minimum of
200 cells were counted.
 
Results
 
Decreased SCL Protein Levels and c-Kit Levels in TF-1 Cells
Expressing an as-SCL.
 
To address SCL function and de-
fine SCL target genes in primitive hemopoietic cells, we
chose to disrupt SCL function in the CD34
 
1
 
/c-kit
 
1
 
 cell
line TF-1. To this end, we took two complementary ap-
proaches. The first one consists of expressing an as-SCL
that interferes with SCL protein levels, and the second one
involves a dn-SCL devoid of its DNA binding domain
(12), which prevents SCL function without affecting pro-
tein levels. We reasoned that loss of SCL function may be
detrimental to the cells and therefore decided to analyze
the cells as early as 1 wk after gene transfer, at a time when
the selective pressure (G418) is already optimal. To mini-
mize cell loss during the selective pressure and, conse-
quently, the generation time required for in vitro expan-
sion, we chose retroviral infection as a method for high
efficiency gene delivery for which we typically obtain 30–
50% transfer efficiency.
We first determined the efficiency of as-SCL in disrupt-
ing SCL protein levels, which were assessed through im-
munostaining of permeabilized cells with the monoclonal
anti-TAL1 antibody BTL73 (Fig. 1). As expected, TF-1
cells express high levels of endogenous SCL. In contrast, 1 wk
after transduction of as-SCL the endogenous SCL protein
level was significantly decreased, with little if any overlap
between the two populations. The cells were further ana-
lyzed for expression of several cell surface markers. Data
shown in Fig. 1 indicate that the fluorescence intensity for
c-Kit (CD117) was at least three- to fourfold lower in dn-
SCL and as-SCL transfectants when compared with paren-
tal TF-1 cells (data not shown) or control cells expressing
the vector alone (
 
MSCV
 
). In contrast, the level of CD45
was not affected by as-SCL or dn-SCL expression and that
of CD116 (GM-CSF receptor 
 
a
 
 chain) was either similar
or slightly higher. Together, the results indicate that de-
creased SCL protein levels (
 
as-SCL
 
) or decreased SCL
function (
 
dn-SCL
 
) specifically lower c-Kit levels without
affecting other surface markers.
Since the GM-CSF receptor is not affected by SCL lev-
els, we proceeded to derive stable TF-1 cell lines expressing
dn-SCL (TF1-dn) following long term selection in G418 in
the presence of GM-CSF as a survival factor, in order to
directly address SCL function at the molecular and cellular
levels. We also established clones that express as-SCL driven
by a weaker promoter, the mouse metallothionein pro-
moter, instead of the strong promoter contained within the
retroviral LTR. Despite this, most of the 50 clones screened
displayed weak levels of transgene expression, consistent
with the reported difficulty in obtaining stable as-SCL
clones in another hemopoietic cell line, K562 (9, 53; and
Figure 1. Flow cytometry analysis of TF-1 transfectants expressing as-
SCL or dn-SCL. (top left) Decreased SCL protein in TF-1 cells expressing
as-SCL. TF-1 cells were infected with a retrovirus harboring the human
SCL cDNA cloned in the antisense orientation and maintained as a poly-
clonal population in GM-CSF containing medium in the presence of
G418 (1 mg/ml). 1 wk after infection, as-SCL transfectants were fixed
and permeabilized with Triton X-100 for nuclear staining with the mono-
clonal anti-TAL1 at a final dilution of 1:10, followed by labeling with a
goat anti–mouse antibody coupled to FITC (Sigma). Cells were washed
extensively for 10 min after each labeling step and analyzed by flow cy-
tometry. Parental TF-1 cells were stained in parallel as positive controls.
Both cell types were also stained with the second antibody alone (2nd) as
negative controls. In contrast to the shift in SCL nuclear staining between
as-SCL transfectants and parental TF-1 cells, those of MSCV (vector alone)
transfectants and TF-1 cells were comparable (data not shown). (top right)
Decreased c-Kit expression in TF-1 cells expressing as-SCL or dn-SCL.
The same cells as in the top left panel were analyzed for surface labeling
with a biotinylated monoclonal antibody against human c-Kit and strepta-
vidin-coupled PE (S-PE). Cells labeled with S-PE alone serve as negative
controls. (middle and bottom) Surface expression of CD45 and CD116
(GM-CSF receptor [GM-R] a chain) is unaltered in TF-1 transfectants.
Cells were labeled with a mouse anti–human CD45 and anti–human
CD116 (GM-R), followed by FITC-labeled goat anti–mouse IgG. Label-
ing with the second antibody alone (2nd) is shown.443 Krosl et al.
Kirsch, I.R., unpublished data). The two highest antisense
expressor clones, A30 and A31, were selected.
We next confirmed that SCL DNA binding activity was
indeed reduced in the antisense clone A31 and the dn-
SCL–expressing transfectants (TF1-dn) through electro-
phoretic mobility shift assays using the TAL1 consensus
probe (reference 21; Fig. 2). TF-1 nuclear extracts pro-
duced four specific complexes (C1–C4), as shown by self-
competition (Fig. 2, lanes 11 and 12). In contrast, a probe
with divergent sequences (mDE2C) did not compete for
binding (data not shown), indicating that these complexes
were specific. All four complexes were also found using
nuclear extracts from Jurkat cells (Fig. 2, lanes 9 and 10)
and TF-1 transfectants harboring the vector alone (TF1-
neo, lanes 1 and 6). The identity of each complex (C1–C4)
was verified by antibody supershifting. Preincubation of
TF1-neo extracts with either anti-SCL or anti-E2A anti-
body supershifted the two most slowly migrating com-
plexes, C1 and C2 (Fig. 2, lanes 1, 2, and 6–8), indicating
that these contain SCL/E2A heterodimers as previously de-
scribed (21, 24). These complexes were absent in HL-60
cells, which were included as a negative control (lane 16).
In the antisense-expressing clone A31, the SCL-containing
complex C1 decreased significantly, whereas the C2 com-
plex was only marginally affected (Fig. 2, compare lanes 3
and 5), suggesting that under conditions where SCL is lim-
iting, the smaller complex, C2, is preferentially formed
over C1. Rescuing clone A31 wild-type SCL (A31-SCL)
restored C1 and C2 binding to the TAL1 probe (Fig. 2,
lanes 3 and 4). In all cell lines, the two fastest migrating
complexes, C3 and C4, were not supershifted with anti-
SCL or anti-E2A, suggesting that these did not contain the
corresponding proteins. These complexes were not affected
in TF1-neo but were decreased in A31, possibly as a conse-
quence of clonal variation, since they were also decreased
in A31-SCL, a subclone of A31.
In the transfectant expressing a dn-SCL, which is a poly-
clonal population, both SCL-containing complexes, C1 and
C2, were significantly decreased relative to TF1-neo whereas
the non-SCL-containing complexes C3 and C4 were not
affected (Fig. 2, compare lanes 5 and 6). Together, our results
indicate that ectopic expression of as-SCL or dn-SCL signifi-
cantly interferes with the formation of the two SCL-contain-
ing complexes, C1 and C2, on the TAL1 probe.
SCL Protein Levels Specify c-kit Expression. As observed
with transient transfectants (Fig. 1), flow cytometry analysis
Figure 2. Decreased SCL DNA binding activity in TF-1 cells expressing as-SCL (A31) or a dn-SCL (TF1-dn). TF-1 cells and the different transfec-
tants were maintained in GM-CSF containing medium. Exponentially growing cells were treated with ZnCl2 for 24 h before preparation of nuclear ex-
tracts. A double-stranded 32P-labeled TAL1 consensus probe was incubated with 25 mg nuclear extracts from TF-1, TF1-neo, A31, A31-SCL, TF1-dn,
Jurkat, and HL-60 as described in Materials and Methods. Unlabeled double-stranded oligonucleotide probes used as competitors were added at 50-fold
molar excess. SCL-containing complexes (black arrows) formed on the TAL1 consensus probe were supershifted (gray arrows) by the monoclonal antibody
anti-SCL/TAL1 or anti-E2A, which were added to the binding reaction. These complexes were displaced by a 50-fold molar excess of self (lanes 4, 13,
and 17) and of the c-kit probe but not by a control probe with divergent sequences, mDE2C (data not shown).444 SCL-dependent Cell Survival and c-kit Expression
of the A31 and TF-1 cells (Fig. 3 A) or TF1-dn and TF1-
neo (data not shown) using a monoclonal antibody to hu-
man c-Kit indicated a quantitative decrease in c-Kit levels
in A31 and TF1-dn as compared with control cells. There
was a direct correlation with c-kit mRNA levels as deter-
mined through Northern blotting (Fig. 3 B). Thus, parental
TF-1 cells or TF-1 cells harboring the vector alone (TF1-
pac and TF1-neo) exhibited comparable levels of c-kit
mRNA (Fig. 3 B). In contrast, c-kit expression was signifi-
cantly lower in A31 and T-dn (Fig. 3, B and C). To ex-
clude the possibility that c-kit mRNA expression was af-
fected by the site(s) of integration in these antisense clones,
we attempted to rescue c-kit expression by wild-type SCL
through retrovirus-mediated gene transfer (MSCV; refer-
ence 43), using puromycin resistance as a second selective
marker. Expression of the puromycin resistance gene alone
did not affect c-kit expression in TF-1 cells (Fig. 3 B, TF1-
pac) nor in A31 cells (data not shown). In contrast, elevat-
ing SCL expression in clone A31 restored c-kit expression
(Fig. 3 B, A31-SCL) and further increased c-kit mRNA
levels in parental TF-1 cells (data not shown). Together,
the results indicate that the targeted attenuation of SCL
protein levels and DNA binding activity directly leads to
decreased c-kit expression.
Sequence analysis of the c-kit promoter revealed two ad-
jacent E boxes at 2374 and 2381 that are conserved be-
tween human and mouse (49), and fit the core binding
motif of MyoD/E2A. Electrophoretic mobility shift assays
indicate that SCL–E2A complexes bind these two E boxes
(our unpublished results), suggesting that these E boxes
may contribute to c-kit promoter activity in response to
SCL. We directly tested SCL transactivation properties on
a chimeric construct in which the luciferase reporter gene
was placed under the control of the human c-kit promoter
(kit1146). Since the endogenous levels of SCL are elevated
in TF-1 cells, we used TF1-dn for transient transfection.
The reporter construct kit1146 was codelivered with vary-
ing amounts of the SCL expression vector MSCV-SCL.
Results shown in Fig. 3 D indicate that SCL induced a
dose-dependent increase in c-kit promoter activity, which
was twofold at an optimum ratio of activator to reporter.
Conversely, cotransfection of dn-SCL and kit1146 in pa-
rental TF-1 cells caused a twofold decrease in luciferase ac-
tivity (data not shown). Together, these results are consis-
tent with the hypothesis that SCL positively regulates c-kit
transcription through binding to two adjacent E boxes in
the c-kit promoter.
Disrupted SCL Function Specifically Prevents SF-dependent
but not GM-CSF or IL-3–dependent Cell Survival. We have
previously shown that both SF and GM-CSF suppress apop-
tosis in TF-1 cells. Parental cells and the different trans-
fectants were, therefore, compared for their survival in
response to optimal concentrations of SF, GM-CSF, or
IL-3. Apoptotic death was revealed by the presence of a
DNA ladder after agarose gel electrophoresis (data not
shown). In the absence of growth factor, there was an in-
tense DNA ladder, suggesting that the cells underwent ap-
optosis. At a concentration of 100 pM of SF, chosen to be
near maximal suppression of apoptosis, parental TF-1 cells
and the control TF1-neo line behaved similarly, with no
detectable DNA degradation. Under identical conditions,
apoptosis was evident in both antisense clones, A30 and
A31 (data not shown), in which SCL protein levels (data
not shown) and DNA binding activity (Fig. 2) were de-
creased. Cell viability was restored in clone A31-SCL, con-
sistent with increased SCL DNA binding activity (Fig. 2,
Figure 3. Reduced c-kit expression in clones expressing an as-SCL:
rescue with wild-type SCL. Cells were maintained in culture with 200
pM GM-CSF in the presence of ZnCl2 for 24 h. (A) Indirect immunoflu-
orescence detection of c-Kit by flow cytometry with the monoclonal an-
tibody against human c-Kit indicates decreased surface expression in A31
and in TF1-dn as compared with parental TF-1 cells or TF1-neo (data
shown for A31 and TF-1). Cells labeled with the second antibody alone
(goat anti–mouse FITC) served as controls, which were similar for A31
and TF-1 (data shown for TF-1). (B and C) RNA extraction and North-
ern blotting were performed as described in Materials and Methods. The
blots were sequentially hybridized with full-length cDNA for human
c-kit, GATA-1, Lyl-1 (data not shown), and GAPDH. The blots were
exposed for 24 h to a PhosphorImager screen. (B and C) After normaliza-
tion with GAPDH and taking TF-1 as 1, c-kit mRNA levels were: 1.05
(TF1-pac), 0.39 (A31), 1.82 (A31-SCL), 1 (TF1-neo), and 0.5 (TF1-dn).
(B) Viable cells were determined through double fluorochrome staining as
described in Materials and Methods. (D) The c-kit promoter construct
kit1146 driving the luciferase reporter gene are codelivered with SCL
into exponentially growing TF1-dn cells by electroporation as described
in Materials and Methods at the indicated activator to reporter ratio. Data
are normalized to that of RSV-GH, cotransfected as an internal control,
and corrected for the effect of SCL on RSV-luciferase, used as an external
standard. Luciferase activity in the absence of activator was taken as 1.
Data are the mean of two independent experiments that were performed
in triplicates.445 Krosl et al.
lane 4) and SCL protein levels (data not shown) in this
clone, whereas control cells expressing the vector alone
(A31-pac) behaved like the parental A31 cell line.
Cell viability was therefore quantitated using the double
fluorochrome staining technique (Fig. 3 B). Full dose–
response curves for SF and GM-CSF were performed in the
two antisense clones, A30 and A31, as well as in control cells.
Data are shown for growth factor concentrations that pro-
vide 80% survival in TF-1 cells (Fig. 3 B). As observed with
agarose electrophoresis, TF-1 and TF1-neo lines remained
viable with SF, whereas A30 and A31 underwent apoptosis.
As above, ectopic SCL expression in clone A31 (A31-SCL)
restored cell viability in SF-containing cultures, indicating
that apoptotic death was due to as-SCL. In contrast, cell
survival was the same in control and antisense clones in
GM-CSF or IL-3 stimulated cultures (data not shown).
Apoptotic cells were also detected through Annexin V
staining of membrane phosphatidyl serine, which is exteri-
orized during apoptotic death, both in stable clones (data
not shown) and in transient transfectants 1 wk after G418
selection. Results shown in Fig. 4 indicate that parental
cells and the different transfectants survive well in GM-
CSF–containing cultures, consistent with their staining pat-
tern for GM-CSF receptor (GM-R) observed in Fig. 1. In
contrast, when the cells were maintained with SF, 80% of
the population expressing dn-SCL or as-SCL was apop-
totic, whereas both controls (TF-1 and MSCV transfec-
tants) survived readily. Impaired survival in response to SF
stimulation in these transfectants is directly correlated with
decreased surface c-Kit expression as shown in Fig. 1. To-
gether, the results suggest that SCL specifically regulates
c-Kit expression and cell survival in response to SF.
Cell Survival in Response to SF Is Rescued by Ectopic SCL or
Ectopic c-kit Expression. As discussed above, the A31 sub-
clone in which endogenous c-kit levels were restored after
ectopic SCL expression, A31-SCL, survived well in cul-
tures stimulated with SF. We, therefore, addressed the pos-
sibility whether c-kit expression by itself was sufficient to
rescue SF-dependent cell viability. Murine c-kit was deliv-
ered to A31 cells through retrovirus-mediated gene trans-
fer, using the LXSN retroviral vector. Despite a high ho-
mology between murine and human c-kit, ligand binding
is species specific such that cells expressing human c-Kit re-
quire five- to eightfold higher concentrations of murine SF
as compared with human SF (Fig. 5 C). After a 2-d selec-
tion in low concentrations of murine SF, c-kit–infected
A31 and TF-1 cells (A31-kit and TF1-kit, respectively)
were expanded with human GM-CSF. Flow cytometry
analysis indicated that .75% of TF1-kit or A31-kit cells
express murine Kit (Fig. 5 A). In GM-CSF–containing cul-
tures, all clones behaved similarly (data not shown). As ex-
pected, TF1-kit responded better than parental TF-1 cells
to murine SF (Fig. 5 C). As with human SF, the response
of A31 cells to murine SF was significantly lower than that
of TF-1 cells, even at saturating concentrations of murine
SF. In contrast, the response of A31-kit to murine SF was
similar to that of TF1-kit, suggesting that c-kit overexpres-
sion was sufficient to overcome the effect of reduced SCL
expression. These observations are compatible with the
view that the major survival function of SCL in TF-1 cells
is mediated through c-kit expression.
SCL Induces c-Kit Expression in a Negative Cell Line.
Ba/F3 is a pro–B cell line that expresses the IL-3 receptor
but not c-Kit (54, 55) or SCL (data not shown). Therefore,
we transduced the human SCL cDNA into Ba/F3 cells
through retroviral infection in order to address the possibil-
ity that SCL can induce c-kit expression in a negative cell
line. Control cells were transduced with the MSCV vector
alone. 2 wk after selection in G418, polyclonal populations
were analyzed for surface expression of murine c-Kit by
flow cytometry (Fig. 6 A). As expected, Ba/F3-MSCV
cells were c-Kit negative. In contrast, Ba/F3-SCL cells
were clearly c-Kit positive.
We next determined whether the cells have acquired re-
sponsiveness to murine SF (Fig. 6 B). In the absence of
growth factor, Ba/F3-SCL transfectants continuously die
over a 3-d period, with the same kinetics as parental Ba/F3
Figure 4. as-SCL or dn-SCL prevents cell survival in response to SF.
Apoptotic cell death is analyzed quantitatively by staining with Annexin
V 6 d after retroviral infection. The indicated transfectants were incubated
for 44 h with a concentration of SF chosen to provide 70–80% survival in
parental TF-1 cells (25% Annexin1 cells), or kept in GM-CSF containing
medium. Cells were stained with propidium iodide and Annexin V–FITC
as described in Materials and Methods. The proportions of Annexin1 cells
are shown in each histogram. Results shown are typical of two indepen-
dent infections.446 SCL-dependent Cell Survival and c-kit Expression
or MSCV transfectants maintained with or without SF. In
contrast, when Ba/F3-SCL transfectants were maintained
with SF, cell numbers remained at input levels for 2 d and
declined slightly on day 3, consistent with the presence of
surface c-Kit on these cells. Together, our observations in-
dicate that enforced SCL expression induces c-Kit and
confers SF responsiveness in Ba/F3 cells.
Discussion
Role of SCL as a Survival Gene: Upregulation of c-kit Ex-
pression. This study provides evidence for a mechanism
whereby SCL secures the survival of primitive hemopoietic
cells through upregulation of the tyrosine kinase receptor
c-Kit, which is itself essential for the generation of he-
mopoietic cells both in vivo and in vitro (17–20). Several
lines of evidence indicate a direct link between SCL and
cell survival in response to SF. First, the apoptotic pheno-
type is induced by both as-SCL and dn-SCL. Second, apop-
tosis in the antisense clone A31 is rescued by ectopic SCL
expression in the sense orientation. Third, apoptosis is spe-
cific to the c-Kit pathway triggered by SF, and is not ob-
served with GM-CSF or IL-3, which indicates exquisite
biological specificity. Indeed, SF is essential for the normal
development of hemopoietic cells, whereas IL-3 and GM-
CSF are produced by activated T cells as part of an inflam-
matory/stress response, suggesting that SCL function is
more important in steady-state hemopoiesis. Finally, en-
forced SCL expression in the pro–B cell line Ba/F3, which
is c-Kit2, clearly induces c-Kit expression in these cells. In
all, our study provides a direct link between SCL and the
survival response of hemopoietic cells to SF, mostly
through upregulation of c-kit transcription.
SCL and Transcription Regulation. The conservation of
two everted E boxes at positions 2381 and 2374 between
the human and mouse promoter sequences (49) suggests a
Figure 5. Survival response to SF rescued by ectopic murine c-kit ex-
pression in as-SCL transfectants. TF-1 cells and the as-SCL–expressing
cells (A31 cells) were infected with MSCV harboring the murine c-kit
gene, or with the pac resistance gene (control) as described in Materials
and Methods. A31-Kit and TF1-Kit (A) as well as A31 and TF-1 (B) were
labeled with ACK2, a monoclonal antibody specific for murine Kit, and a
goat anti–rat Ig coupled to FITC (solid lines). Cells labeled with the sec-
ond antibody alone served as negative controls (broken lines). For apoptosis
assay, cells were maintained with the indicated concentrations of murine
SF for 2 d. Viable cells were determined by trypan blue exclusion. (C) The
half efficient concentration of murine SF for the different clones were:
TF-1, 17.8 6 2.1; A31, 13 6 4; TF1-kit, 3.5 6 0.5; A31-kit, 4.3 6 0.6.
Figure 6. SCL induces c-Kit expression in pro–B cell line Ba/F3. (top)
After retroviral-mediated gene transfer, polyclonal populations with en-
forced SCL expression (Ba/F3-SCL) or control cells harboring the vector
alone (Ba/F3-MSCV) were labeled with the monoclonal rat anti–murine
c-Kit as in Fig. 5. (bottom) Viable cell counts from cultures stimulated with
optimal concentrations of murine SF were determined through trypan blue
exclusion. Cell counts for growth factor–deprived Ba/F3 and Ba/F3-MSCV
(data not shown) were comparable to those observed with murine SF.447 Krosl et al.
functional role in transcription regulation, which was con-
firmed through binding studies (data not shown) and pro-
moter deletion analysis. Our gel shift assays indicate that
SCL-containing complexes that are formed on the c-kit
probe also include E2A, consistent with the view that SCL
does not bind DNA on its own and requires interaction with
E12, E47, or HEB, another ubiquitous basic helix-loop-helix
(21, 24). Furthermore, SCL is also found in association with
the LIM-only protein Rbtn2/Lmo2 (22, 23) in a multipro-
tein complex with GATA-1 and a LIM-binding protein,
Ldb1 (24). An E box–GATA motif was identified through in
vitro binding site selection with nuclear extracts instead of
isolated proteins (24), which corresponds strikingly to the
c-kit everted E box sequences at 2381. Sequence analysis of
the human c-kit promoter also reveals the presence of several
potential GATA sites at 2900. Although these are found up-
stream instead of downstream of the E box as in the CAST-
ing experiment, it is possible that a looping mechanism fa-
vored by protein–protein association allows for optimal spatial
arrangements such as those defined by CASTing.
Transactivation assays indicate that SCL represses the
E2A-dependent activity of a promoter construct containing
the TAL1 motif. It is only in the presence of Id that SCL
was shown to relieve the inhibition conferred by Id1 on
E2A (7). In addition, despite its high affinity binding to the
Ebox-GATA motif, the SCL–E2A heterodimer has no ac-
tivity on a reporter construct with a minimal promoter
linked to two such motives, either in the absence or pres-
ence of Lmo2. This multiprotein complex, however, pro-
vides a twofold enhancement of luciferase activity driven
by GATA-1 on the same construct (24). Thus, SCL ap-
pears to be a weak transactivator, consistent with our results
indicating a twofold contribution to the activity of the
proximal c-kit promoter in TF-1 cells. This twofold con-
tribution was confirmed by three distinct approaches,
Northern blotting for steady state c-kit mRNA levels, flow
cytometry analysis of surface c-Kit protein, and analysis of
the c-kit promoter driving the luciferase reporter gene. A
recent report using semiquantitative reverse transcriptase
PCR did not detect significant differences in c-kit mRNA
levels in embryoid bodies grown from scl2/2 embryonic
stem and wild-type embryonic stem cells (56). However, it
should be noted that flow cytometry analysis and luciferase
activity can quantitatively reveal a two- to fourfold differ-
ence, whereas reverse transcriptase PCR remains semiquan-
titative and requires much larger differences for detection.
Implication for Leukemogenesis. It was previously shown
that loss of SCL function is associated with premature apop-
tosis upon nutrient deprivation in the lymphoid cell line Jur-
kat (42) and decreased colony formation in the erythroid cell
line K562 (53), suggesting a role for SCL in mediating cell
survival. As observed with the antiapoptotic gene bcl-2,
which infrequently induces lymphomas in transgenic mice
after a long latency period of 18 mo (57), elevating SCL
expression in thymocytes is not sufficient to cause tumors in
transgenic mice (58). Directing SCL expression in the thymus
can nonetheless shorten the time of appearance of T cell tu-
mors in LMO-2 (59), LMO-1 (58), or casein kinase II trans-
genic mice (48). Although these observations suggest a role
for SCL in leukemogenesis, its target genes remain unknown.
The cells that repopulate the thymus and a subpopulation
of triple negative thymocytes are c-Kit1 (37). Interestingly,
SF is expressed by fetal thymic stromal cells and epithelial
cells (38, 39, 60). More importantly, T cell differentiation
in thymic lobe reconstitution with fetal liver precursors is
inhibited by anti-Kit (37) and is impaired in white spotting
mice, indicating the functional importance of c-Kit (61). In
parallel, the presence of SCL mRNA in a subset of thy-
mocytes (11) and the absolute requirement in SCL for the
generation of T cells in vivo (19, 20) are indicative of the
importance of SCL for thymocyte development. Our ob-
servations suggest that SCL may also specify c-Kit expres-
sion in primitive thymocytes to sustain cell survival in re-
sponse to SF. Consistent with this, elevating SCL levels in
thymocytes in double CD2-SCL and CD2-Lmo2 trans-
genics results in a twofold expansion of the double negative
CD42/CD82 thymocyte population relative to CD2-
Lmo2 transgenics (48), which, in light of our results, may
be due to an increase in c-Kit1 subpopulations. We pro-
pose that constitutive SCL expression in the T cell lineage
caused by chromosomal rearrangements results in constitu-
tive c-kit expression in primitive thymocytes and prolongs
their survival, which may represent an initiating event in T
cell ALL. Secondary events are probably involved in the
full development of T cell leukemia (58, 62), a mechanism
commonly observed in tumor biology (63).
Tissue-specific Transcription Factors and Cell Survival.
The regulation of cell survival is central to normal develop-
mental processes and stress response. It is widely accepted
that survival cues are crucial for the differentiation process
(64), and emerging evidence suggests a novel role for tis-
sue-specific transcription factors, otherwise important for
driving a defined pattern of gene expression, in regulating
cell survival. Thus, the zinc finger transcription factor
GATA-1 is required for terminal maturation in the eryth-
roid lineage (65). GATA-1 gene ablation in embryonic
stem cells blocks the differentiation at the proerythroblast
stage (65, 66) and causes apoptotic death (66). Similarly,
GATA-4 is required for cardiomyocyte differentiation from
embryonal carcinoma cells (67) and cell survival in the car-
diomyocyte pathway but not the neuronal lineage. Hence,
apoptosis may be linked to insufficient survival signals, but
also to inefficient or abortive cell differentiation. Similarly,
SCL is required early in hemopoiesis, possibly in specifying
ventral mesoderm to the hemopoietic fate (19), and is
shown here to be crucial for SF-mediated cell survival.
Therefore, it is proposed that lineage-specific transcription
factors orchestrate both lineage-specific gene expression
and the survival of the specified cell types.448 SCL-dependent Cell Survival and c-kit Expression
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